Advertisement

American Gastroenterological Association Institute Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy

Published:October 31, 2014DOI:https://doi.org/10.1053/j.gastro.2014.10.039
      This document presents the official recommendations of the American Gastroenterological Association (AGA) on the prevention and treatment of hepatitis B virus reactivation (HBVr) during immunosuppressive therapy. The guideline was developed by the Clinical Practice and Quality Measures Committee (currently the Clinical Practice Guideline Committee) and approved by the AGA Governing Board.

      Abbreviations used in this paper:

      AGA (American Gastroenterological Association), anti-HBc (antibody to hepatitis B core antigen), anti-HBs (antibody to hepatitis B surface antigen), CI (confidence interval), GRADE (Grading of Recommendations Assessment, Development and Evaluation), HBsAg (hepatitis B surface antigen), HBV (hepatitis B virus), HBVr (hepatitis B virus reactivation)
      To read this article in full you will need to make a payment
      AGA Member Login
      Login with your AGA username and password.
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. American Gastroenterological Association. AGA Institute clinical practice guideline development process. January 2013. http://www.gastro.org/practice/medical-position-statements/aga-institute-clinical-practice-guideline-development-process.

        • Sultan S.
        • Falck-Ytter Y.
        • Inadomi J.M.
        The AGA Institute process for developing clinical practice guidelines part one: grading the evidence.
        Clin Gastroenterol Hepatol. 2013; 11: 329-332
        • Institute of Medicine
        Clinical practice guidelines we can trust.
        Institute of Medicine, Washington, DC2011
        • Perrillo R.P.
        • Gish R.
        • Falck-Ytter Y.T.
        American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.
        Gastroenterology. 2015; 148: 221-244

      Linked Article

      • Correction
        GastroenterologyVol. 148Issue 2
        • Preview
          Reddy KR, Beavers KL, Hammond SP, et al. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 2015;148:215–219.
        • Full-Text
        • PDF